1. Search Result
Search Result
Results for "

Foxo3a

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

2

Natural
Products

1

Recombinant Proteins

4

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15186
    Ipatasertib
    Maximum Cited Publications
    45 Publications Verification

    GDC-0068; RG7440

    Organoid Akt Apoptosis Cancer
    Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .
    Ipatasertib
  • HY-16558
    Butein
    4 Publications Verification

    2’,3,4,4’-tetrahydroxy Chalcone

    EGFR Autophagy Apoptosis Phosphodiesterase (PDE) Cancer
    Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60 c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a [3]. Butein is a SIRT1 activator (STAC).
    Butein
  • HY-148509

    Others Cancer
    PhosTAC5 is a phosphorylation targeting chimera (PhosTAC) molecule composed of a linker with fivePEG groups. PhosTAC5 induces dephosphorylation of PDCD4 and FOXO3a .
    PhosTAC5
  • HY-148508

    Others Cancer
    PhosTAC3 is a phosphorylation targeting chimera (PhosTAC) molecule composed of a linker with three PEG groups. PhosTAC3 induces dephosphorylation of PDCD4 and FOXO3a .
    PhosTAC3
  • HY-153347
    JY-2
    1 Publications Verification

    FOXO Metabolic Disease
    JY-2 is a moderately selective and orally active Forkhead transcription factor forkhead box O1 (FoxO1) inhibitor that inhibits FoxO1 transcriptional activity with an IC50 of 22 μM. JY-2 shows moderate inhibition against FoxO3a and FoxO4. JY-2 shows anti-diabetic activity .
    JY-2
  • HY-RS23067

    Fkhrl1; Foxo3a

    Small Interfering RNA (siRNA) Others

    Foxo3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Foxo3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Foxo3 Rat Pre-designed siRNA Set A
    Foxo3 Rat Pre-designed siRNA Set A
  • HY-RS05070

    Foxo2; AF6q21; FKHRL1; Foxo3a; FKHRL1P2

    Small Interfering RNA (siRNA) Others

    FOXO3 Human Pre-designed siRNA Set A contains three designed siRNAs for FOXO3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FOXO3 Human Pre-designed siRNA Set A
    FOXO3 Human Pre-designed siRNA Set A
  • HY-RS16632

    Fkhr2; FKHRL1; Foxo3a; 1110048B16Rik; 2010203a17Rik

    Small Interfering RNA (siRNA) Others

    Foxo3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Foxo3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Foxo3 Mouse Pre-designed siRNA Set A
    Foxo3 Mouse Pre-designed siRNA Set A
  • HY-15186C

    GDC-0068 tosylate; RG7440 tosylate

    Organoid Akt Apoptosis Cancer
    Ipatasertib (GDC-0068) tosylate is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib tosylate synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib tosylate also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .
    Ipatasertib tosylate
  • HY-16558R

    2’,3,4,4’-tetrahydroxy Chalcone (Standard)

    Reference Standards EGFR Autophagy Apoptosis Phosphodiesterase (PDE) Cancer
    Butein (Standard) is the analytical standard of Butein. This product is intended for research and analytical applications. Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a [3]. Butein is a SIRT1 activator (STAC).
    Butein (Standard)
  • HY-162050

    Sirtuin Neurological Disease
    8AQ?Cu?5Iu is an activator of SIRT1. 8AQ?Cu?5Iu exhibits neuroprotective effects by modulating the SIRT1/3-FOXO3a signaling pathway. 8AQ?Cu?5Iu can used in study attenuating neurodegenerative diseases .
    8AQ−Cu−5Iu
  • HY-145232
    PhosTAC7
    2 Publications Verification

    Phosphatase Tau Protein Neurological Disease Cancer
    PhosTAC7 is a heterobifunctional molecule named as a Phosphorylation Targeting Chimera (PhosTAC). PhosTAC7 can dephosphorylate the PDCD4 protein, FOXO3a protein, and Tau protein by recruiting serine/threonine protein phosphatase 2A (PP2A). PhosTAC7 offers the advantage of selectively modulating the phosphorylation state of individual target proteins, making it a promising tool for research in cancer and tau protein-related neurodegenerative diseases .
    PhosTAC7
  • HY-116604

    PD 139530

    PI3K Akt Cancer
    RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness. RLX highlights the necessity for further research into the tumor microenvironment’s dynamics to develop more tailored treatment approaches for diverse tumor types.
    RLX

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: